Table 1 Distribution of 68 lung cancer cases and 337 controls, according to matching variables
From: Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection
Lung cancer | Controls | |||
|---|---|---|---|---|
N | (%) | N | (%) | |
Centre | ||||
Basel | 11 | 16.2 | 55 | 16.3 |
Bern | 9 | 13.2 | 42 | 12.5 |
Geneva | 15 | 22.1 | 75 | 22.3 |
St Gallen | 7 | 10.3 | 35 | 10.4 |
Vaud | 13 | 19.1 | 65 | 19.3 |
Zurich | 13 | 19.1 | 65 | 19.3 |
Gender | ||||
Male | 54 | 79.4 | 270 | 80.1 |
Female | 14 | 20.6 | 67 | 19.9 |
HIV-transmission category | ||||
MSM | 19 | 27.9 | 95 | 28.2 |
IDU | 25 | 36.8 | 125 | 37.1 |
Het/other | 24 | 35.3 | 117 | 34.7 |
Age at lung cancer a (years) | ||||
25–44 | 24 | 35.3 | 132 | 39.2 |
45–54 | 26 | 38.2 | 122 | 36.2 |
55–64 | 13 | 19.1 | 61 | 18.1 |
⩾65 | 5 | 7.4 | 22 | 6.5 |
Duration of follow-up before lung cancer a (months) | ||||
<24 | 11 | 16.2 | 55 | 16.3 |
24–59 | 13 | 19.1 | 65 | 19.3 |
⩾60 | 44 | 64.7 | 217 | 64.4 |
Calendar period at lung cancer a | ||||
1985–1991 | 3 | 4.4 | 15 | 4.5 |
1992–1996 | 6 | 8.8 | 30 | 8.9 |
1997–April 2000 | 6 | 8.8 | 31 | 9.2 |
May 2000b–2005 | 28 | 41.2 | 146 | 43.3 |
2006–2010 | 25 | 36.8 | 115 | 34.1 |
